Redx Pharma (REDX)

Sector:

Pharma and Biotech

18.20p
   
  • Change Today:
    -0.55p
  • 52 Week High: 36.00
  • 52 Week Low: 17.50
  • Currency: UK Pounds
  • Shares Issued: 388.99m
  • Volume: 42,520
  • Market Cap: £70.80m
  • RiskGrade: 278

Redx Pharma nominates next drug development candidate

By Josh White

Date: Thursday 09 Jan 2020

LONDON (ShareCast) - (Sharecast News) - Drug discovery and development company Redx Pharma announced the nomination of RXC007 as its next drug development candidate for the treatment of fibrosis on Thursday.
The AIM-traded firm described RXC007 as a "novel and selective" rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, which is an enzyme that sits at a nodal point in cell signalling pathways believed to be central to fibrosis.

It said fibrosis is a "key pathogenic factor" in multiple diseases with high unmet medical need, and ROCK2 is therefore an important emerging drug target, with RXC007 to be developed as a best-in-class drug to target several fibrotic diseases.

Those would include the orphan disease idiopathic pulmonary fibrosis (IPF), which is a severe and life-threatening chronic lung condition with very poor prognosis and limited treatment options, as well as non-alcoholic steatohepatitis (NASH), an inflammatory and fibrotic disease of the liver, and diabetic nephropathy, which is a serious diabetic kidney disease.

Redx said preclinical data with compounds from its ROCK2 programme had demonstrated robust anti-fibrotic effects in a range of industry-standard in vivo models.

Specifically, RXC007 - which is orally bioavailable - reportedly met fibrosis endpoints in disease models of liver and lung fibrosis.

Additionally, RXC007's selective inhibition of ROCK2 over other enzyme isoforms should enable a safe cardiovascular profile in patients, the company claimed.

It said Dr Nicolas Guisot, research fellow at Redx, recently presented preclinical data from this programme at the third annual Anti-fibrotic Drug Development (AFDD) conference in Boston in November.

The firm said it was aiming to initiate a phase 1 study with RXC007 in the first half of 2021, while evaluating clinical development pathways in IPF and potentially in other disease areas.

It was the second development candidate that Redx had progressed in the area of fibrosis following the nomination of RXC006, which is a novel, orally available porcupine inhibitor, that it was developing as a first-in-class treatment for IPF.

"Redx is pleased to be progressing the development of this exciting drug candidate that selectively inhibits ROCK2 as a potential treatment for multiple fibrotic diseases," said chief executive officer Lisa Anson.

"This is a challenging area of chemistry and the Redx team is proud to deliver another successful drug candidate.

"We look forward to taking RXC007 into clinical trials in the first half of 2021."

At 1107 GMT, shares in Redx Pharma were down 1.21% at 8.15p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Redx Pharma Market Data

Currency UK Pounds
Share Price 18.20p
Change Today -0.55p
% Change -2.93 %
52 Week High 36.00
52 Week Low 17.50
Volume 42,520
Shares Issued 388.99m
Market Cap £70.80m
RiskGrade 278

Redx Pharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
61.01% below the market average61.01% below the market average61.01% below the market average61.01% below the market average61.01% below the market average
88.89% below the sector average88.89% below the sector average88.89% below the sector average88.89% below the sector average88.89% below the sector average
Price Trend
72.69% below the market average72.69% below the market average72.69% below the market average72.69% below the market average72.69% below the market average
26.32% below the sector average26.32% below the sector average26.32% below the sector average26.32% below the sector average26.32% below the sector average
Income Not Available
Growth
28.23% below the market average28.23% below the market average28.23% below the market average28.23% below the market average28.23% below the market average
35.14% below the sector average35.14% below the sector average35.14% below the sector average35.14% below the sector average35.14% below the sector average

What The Brokers Say

Strong Buy 0
Buy 1
Neutral 0
Sell 0
Strong Sell 0
Total 1
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Redx Pharma Dividends

No dividends found

Trades for 28-Mar-2024

Time Volume / Share Price
09:50 10 @ 18.95p
09:49 10 @ 18.95p
08:26 22,500 @ 18.00p
08:16 10,000 @ 18.08p
08:15 10,000 @ 18.08p

Top of Page